AU GU ST 7 , 2 0 2 3 mCRC Program Update and Clinical Development Plan PFIZER We expect clinical data from our 1st line RAS-mutated mCRC trial in mid-2024 mCRC clinical development program agreed with FDA • &#x202

AU GU ST 7 , 2 0 2 3 mCRC Program Update and Clinical Development Plan PFIZER We expect clinical data from our 1st line RAS-mutated mCRC trial in mid-2024 mCRC clinical development program agreed with FDA • • • • • • 5 3 Annual eligible U.S. patients ('000s)* 15 12 40 0 50 23 48 Line of Therapy Ph2 Ph3 Investigator-initiated trials Trial Combination with: CLINICAL FINDINGS FROM 2L Ph 1b/2 TRIAL SCIENTIFIC BASIS FOR CLINICAL FINDINGS CLINICAL DEVELOPMENT PATH FORWARD Onvansertib clinical development plan in mCRC CLINICAL FINDINGS FROM 2L Ph 1b/2 TRIAL SCIENTIFIC BASIS FOR CLINICAL FINDINGS CLINICAL DEVELOPMENT PATH FORWARD Onvansertib clinical development plan in mCRC Onvansertib PROPERTIES SPECIFICITY • • • 1st LINE 2nd Normal LINE RAS Mutated 2nd Normal 1st LINE LINE RAS Mutated MOA 21 RAS-mutations in mCRC1 28 DAY CYCLE ENROLLMENT CRITERIA EFFICACY ENDPOINTS 1 2 3 PHASE 1b PHASE 2 ITT population (N) 50 68 Evaluable population* (N) 48 66 We enrolled 50 initial patients, and then an additional 18 patients, in our trial TOTAL 1st LINE 2nd Bev exposed vs bev naïve patients LINE KRAS Variant CR+PR SD PD Total G12C G12D G12V G13D G12S G12A Q61H G13C • • • • • • • TEAE GR1 GR2 GR3 GR4 TOTAL TEAE GR1 GR2 GR3 GR4 TOTAL Fatigue 24 22 7 0 53 78% Cough 11 0 0 0 11 16% Neutropenia 1 18 23 7 49 72% Pyrexia 8 1 1 0 10 15% Nausea 29 13 4 0 46 68% Dyspnea 7 3 0 0 10 15% Diarrhea 21 13 4 0 38 56% AST Increase 7 2 1 0 10 15% Leukopenia 9 14 5 1 29 43% Lymphocytopenia 2 7 0 0 9 13% Anemia 22 5 2 0 29 43% Dyspepsia 9 0 0 0 9 13% Alopecia 20 5 0 0 25 37% ALT Increase 8 0 1 0 9 13% Abdominal Pain 14 8 3 0 25 37% Hypocalcemia 9 0 0 0 9 13% Stomatitis 15 6 3 0 24 35% Insomnia 9 0 0 0 9 13% Hypertension 4 10 9 0 23 34% Dehydration 1 5 2 0 8 12% Thrombocytopenia 17 5 1 0 23 34% Hypokalemia 6 2 0 0 8 12% Constipation 17 2 1 0 20 29% Arthralgia 6 2 0 0 8 12% Vomiting 11 6 3 0 20 29% Hand / Foot Syndrome 5 2 0 0 7 10% Epistaxis 15 0 0 0 15 22% Hemorrhoids 5 2 0 0 7 10% Headache 13 0 0 0 13 19% Non-Cardiac Chest Pain 6 1 0 0 7 10% Decreased Appetite 4 6 2 0 12 18% ALP Increase 5 1 1 0 7 10% Back Pain 10 2 0 0 12 18% CLINICAL FINDINGS FROM 2L Ph 1b/2 TRIAL SCIENTIFIC BASIS FOR CLINICAL FINDINGS CLINICAL DEVELOPMENT PATH FORWARD Onvansertib clinical development plan in mCRC Our findings establish the scientific basis of our bev naïve clinical finding Tumor volume (mm 3 ) 0 10 20 30 0 500 1000 1500 2000 2500 SW620 (KRAS G12V) The combination had significant superior anti-tumor activity compared to the single agents KRAS-mut tumors from mice treated with onv + bev appear smaller and pale (less vascularized) •••••• PLK1 inhibition using siRNA against PLK1 (siPLK1) prevented hypoxia-induced HIF1a expression In 4 RAS-mutant CRC cell lines*, onvansertib inhibited hypoxia-induced HIF1a expression This new MOA, which inhibits a “survival switch” of tumorigenesis, may underlie the increased efficacy observed clinically • • • – – • • RAS-mutations in mCRC1 MOA 2 1 3 CLINICAL FINDINGS FROM 2L Ph 1b/2 TRIAL SCIENTIFIC BASIS FOR CLINICAL FINDINGS CLINICAL DEVELOPMENT PATH FORWARD Onvansertib clinical development plan in mCRC • • 2nd line mCRC 1st line mCRC • …and FDA agreed with Cardiff Oncology's proposed 1st line clinical program FDA suggested we consider moving to a 1st line clinical development path… • • • Clinical Commercial • • Transition from 2L to 1L Regulatory • • • • ENROLLMENT CRITERIA ENDPOINTS Primary Secondary Benchmark of success 2 nd Line mCRC 1 st line mCRC 2 nd Line mCRC 1 st line mCRC BREAKTHROUGH GROWTH INITIATIVE • • • PFIZER PFIZER Ignite • • 2023 2024 2025 PFIZER We expect clinical data from ou